Archive for the 'Lung Cancer' Category
Genetic Test For Lung Cancer Recurrence?
The goal of developing reliable genetic tests to guide lung cancer treatment has taken a step forward. Researchers at Columbia University recently evaluated the ability of five high-risk genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non-small cell lung cancer was caught early and surgically removed. They will present their findings at the American Thoracic Society’s 2008 International Conference in Toronto on Tuesday, May 20.Original post by Diabetes Notes
No commentsPotential Blood Test For Lung Cancer
A simple blood test may be able to detect lung cancer in its earliest stages with unprecedented accuracy, according to new research to be presented at American Thoracic Society’s 2008 International Conference in Toronto on Tuesday, May 20.Original post by Diabetes Notes
No commentsNew Pfizer Data In Lung Cancer, Ewing’s Sarcoma, Prostate Cancer And Other Difficult-to-Treat Tumor Types To Be Presented At ASCO
Pfizer announced that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008.Researchers will present the latest data from the breadth of Pfizer’s oncology portfolio, focused in four areas of discovery: anti-angiogenesis, signal transduction, immuno-oncology and cytotoxics/potentiators.Original post by Diabetes Notes
No commentsAsbestos-Induced Lung Cancer Patients Do Not Appear To Benefit From Chemotherapy, UK
Adding chemotherapy to established methods of symptom management does not appear to enhance the quality of life or survival of patients suffering from an asbestos-induced form of lung cancer called malignant plural mesothelioma (MPM). These are the results of MS01, a large UK and Australian study published in the Lancet, which set out to assess the potential benefits of combining active symptom control (ASC) with chemotherapy.Original post by Diabetes Mine
No commentsASCO Study Confirms Importance Of Histology In Treatment Of Non Small Cell Lung Cancer With ALIMTA (pemetrexed For Injection)
Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved Eli Lilly and Company’s ALIMTA® (pemetrexed for injection), will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., May 30 — June 3, 2008.Original post by Diabetes Mine
No commentsPost-Surgery Exercise Benefits Lung Cancer Patients
Patients who have undergone surgical procedures for the removal of lung cancer can tolerate and benefit from exercise regimens started just a month after surgery, according to a new study led by researchers at the Duke Comprehensive Cancer Center.Original post by Diabetes Mine
No commentsCelebrex Shows Benefit In First-of-Its-Kind Lung Cancer Chemoprevention Trial
Celecoxib, the anti-inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center. This finding demonstrates the significance of COX-2 inhibition toward preventing lung cancer in individuals at higher risk of developing the disease.Original post by Diabetes Mine
No commentsHow Smoking Causes Cancer Pinpointed By OHSU Cancer Institute Researchers
Oregon Health & Science University Cancer Institute researchers have pinpointed the protein that can lead to genetic changes that cause lung cancer.The research is published in the British Journal of Cancer.Researchers discovered that the production of a protein called FANCD2 is slowed when lung cells are exposed to cigarette smoke. Low levels of FANCD2 leads to DNA damage, triggering cancer.Original post by Diabetes Mine
No commentsGSL Receives Authorisation In Europe For Oral Hycamtin(R) (topotecan Hard Capsules) For The Treatment Of Relapsed Small Cell Lung Cancer
GlaxoSmithKline (GSK) announced that oral Hycamtin® (topotecan hard capsules) have received approval from the European Commission for the treatment of relapsed SCLC. Specifically, topotecan hard capsules are indicated as monotherapy for the treatment of adult patients with relapsed SCLC (PS0-2 [*]) [1] for whom re-treatment with the first-line regimen is not considered appropriate.Original post by World of Psychology
No commentsVicus Therapeutics Records Last Patient Visit Of Phase 2, VT-122 Trial For The Treatment Of Cachexia In Patients With Advanced Lung Cancer
Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced today the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of VT-122. The compound was tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The Phase 2 clinical trial was conducted in India and the final study report is expected in June 2008.Original post by Diabetes Update
No comments